{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:50Z","timestamp":1793374250992,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King&apos;s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027043","name":"Milken Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022974","name":"Global Alliance for Chronic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euroneuro.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:14:21Z","timestamp":1719843261000},"page":"58-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression"],"prefix":"10.1016","volume":"85","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-4709","authenticated-orcid":false,"given":"Istvan","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-380X","authenticated-orcid":false,"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yordan","family":"Godinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-3676","authenticated-orcid":false,"given":"Philip","family":"Gorwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-638X","authenticated-orcid":false,"given":"Tetsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-3007","authenticated-orcid":false,"given":"Albino J.","family":"Oliveira-Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9145-3790","authenticated-orcid":false,"given":"Tamara","family":"Werner-Kiechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2024.05.009_bib0001","unstructured":"European Medicines Agency. 2013. Guideline on clinical investigation of medicinal products in the treatment of depression. EMA\/CHMP\/185423\/2010 Rev 2. Available at: https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific-guideline\/wc500143770_en.pdf."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0002","unstructured":"European Medicines Agency. 2014. Questions and answers on Seroquel, Seroquel XR and associated names (quetiapine). August 2014, Accessed August 2014. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/questions-answers-seroquel-seroquel-xr-associated-names-quetiapine_en.pdf."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0003","unstructured":"European Medicines Agency. 2019a. Seroquel XR: summary of product characteristics 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/seroquel-xr-article-613-referral-annex-i-ii-iii-iv_en.pdf."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0004","unstructured":"European Medicines Agency. 2019b. Spravato: summary of product characteristics 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0005","series-title":"HSD28 most common treatments in patients with treatment resistant depression based on European cohort study real-world evidence","first-page":"S278","author":"Heerlein","year":"2022"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0006","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jad.2021.03.073","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: treatment patterns and clinical outcomes","volume":"290","author":"Heerlein","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0007","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1192\/bjp.179.42.s4","article-title":"Clinical importance of long-term antidepressant treatment","volume":"42","author":"Hirschfeld","year":"2001","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euroneuro.2023.03.001","article-title":"The elephant in the room: medication as confounder","volume":"71","author":"Ilzarbe","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0009","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/NDT.S241780","article-title":"Prevalence and determinants of long-term utilization of antidepressant drugs: a retrospective cohort study","volume":"16","author":"Lunghi","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12991-023-00478-7","article-title":"Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel","volume":"22","author":"Maina","year":"2023","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0014","unstructured":"MedDRA. 2024. Medical dictionary for regulatory activities, Accessed January. https:\/\/www.meddra.org\/."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0015","unstructured":"National Institute for Health and Care Excellence. 2022. NICE guideline NG222, Depression in adults, [E] Chronic depression."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0016","unstructured":"Nationale Versorgungs Leitlinien. 2022. Nationale versorgungs leitlinie: unipolare depression version 3.0."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320954616","article-title":"Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England","volume":"10","author":"Osborne","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0018","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0019","first-page":"18m02340","article-title":"Factors that impact treatment decisions: results from an online survey of individuals with bipolar and unipolar depression","volume":"20","author":"Rosenblat","year":"2018","journal-title":"Prim. Care Companion. CNS. Disord."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","article-title":"Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression","volume":"243","author":"Rosenblat","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0021","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0022","unstructured":"U.S. Food and Drug Administration. 2020. SEROQUEL XR (quetiapine fumarate extended release) prescribing information March 2020."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0023","unstructured":"U.S. Food and Drug Administration. 2023. SPRAVATO\u00ae (esketamine nasal spray) prescribing information October 2023."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0024","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2011.11.011","article-title":"Head to head comparisons as an alternative to placebo-controlled trials","volume":"22","author":"Vieta","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0026","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0027","unstructured":"WHO Collaborating Centre for International Drug Monitoring. 1992. WHO drug dictionary.: uppsala: WHO collaborating centre for international drug monitoring."},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0028","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0029","series-title":"Presented at 36th European College of Neuropsychopharmacology (ECNP) congress","first-page":"P0636","article-title":"Long-term safety and maintenance of response with Esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 Study","author":"Young","year":"2023"},{"key":"10.1016\/j.euroneuro.2024.05.009_bib0030","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2400124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2400124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:44:43Z","timestamp":1778766283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2400124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"alternative-id":["S0924977X2400124X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.05.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}